Go Pro

Varma Mutual Pension Insurance Co Takes $14.10 Million Position in Astera Labs, Inc. $ALAB

Astera Labs logo with Technology background
Image from MarketBeat Media, LLC.

Varma Mutual Pension Insurance Co bought a new position in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 29,200 shares of the company's stock, valued at approximately $14,104,000.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new stake in Astera Labs during the 2nd quarter worth approximately $6,609,581,000. Atreides Management LP raised its position in Astera Labs by 108.9% in the 1st quarter. Atreides Management LP now owns 3,365,787 shares of the company's stock valued at $368,890,000 after purchasing an additional 1,754,593 shares during the last quarter. Amundi boosted its stake in Astera Labs by 1,298.6% in the third quarter. Amundi now owns 1,421,263 shares of the company's stock worth $278,283,000 after purchasing an additional 1,319,643 shares in the last quarter. Artisan Partners Limited Partnership acquired a new position in Astera Labs in the fourth quarter worth $148,980,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Astera Labs by 189.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,312,927 shares of the company's stock worth $218,419,000 after purchasing an additional 858,693 shares during the last quarter. Institutional investors and hedge funds own 60.47% of the company's stock.

Insider Buying and Selling

In other news, Director Jack R. Lazar sold 10,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $355.17, for a total transaction of $3,551,700.00. Following the completion of the sale, the director owned 75,688 shares of the company's stock, valued at $26,882,106.96. This represents a 11.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Manuel Alba sold 136,974 shares of the firm's stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $442.01, for a total transaction of $60,543,877.74. Following the sale, the director owned 1,287,524 shares in the company, valued at approximately $569,098,483.24. The trade was a 9.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 419,244 shares of company stock valued at $163,135,169. 10.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ALAB has been the subject of a number of research reports. Rothschild & Co Redburn initiated coverage on shares of Astera Labs in a report on Friday, May 1st. They issued a "neutral" rating and a $153.00 price target for the company. Susquehanna raised their price objective on shares of Astera Labs from $230.00 to $275.00 and gave the company a "neutral" rating in a research note on Friday, July 31st. Barclays upped their target price on shares of Astera Labs from $200.00 to $325.00 and gave the company an "equal weight" rating in a research report on Monday, July 20th. Roth Capital reissued a "buy" rating and issued a $450.00 price target on shares of Astera Labs in a research note on Wednesday, August 5th. Finally, Stifel Nicolaus raised their price target on Astera Labs from $260.00 to $460.00 and gave the stock a "buy" rating in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $333.00.

Get Our Latest Report on Astera Labs

Astera Labs Stock Performance

NASDAQ:ALAB opened at $284.97 on Monday. Astera Labs, Inc. has a 1 year low of $97.89 and a 1 year high of $499.48. The stock has a 50-day moving average price of $352.70 and a two-hundred day moving average price of $245.57. The stock has a market cap of $49.44 billion, a price-to-earnings ratio of 141.07 and a beta of 3.84.

Astera Labs (NASDAQ:ALAB - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.80 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.11. Astera Labs had a return on equity of 19.24% and a net margin of 30.74%.The company had revenue of $392.40 million for the quarter, compared to analyst estimates of $360.85 million. During the same quarter last year, the firm posted $0.44 earnings per share. Astera Labs's revenue was up 104.5% compared to the same quarter last year. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. Sell-side analysts forecast that Astera Labs, Inc. will post 2.7 earnings per share for the current year.

Astera Labs Company Profile

(Free Report)

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company's product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.

Recommended Stories

Institutional Ownership by Quarter for Astera Labs (NASDAQ:ALAB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Astera Labs Right Now?

Before you consider Astera Labs, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astera Labs wasn't on the list.

While Astera Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines